All the Active Ingredient Drugs
Protein Kinase Inhibitor. Midostaurin 25 mg. SOFT. CAPS.: 56, 112. The recom. dose is 50 mg ×2/d. Midostaurin is dosed on 8th d.- 21st d. of induct. and consolidate. chemother. cycles and then twice dly. as single-agent mainten. ther. for 12 mnths.
Dosing for advanc. SM: The recom. init. dose is 100 mg ×2/d. Tmt. should be contin.as long as clinic. benefit is observed or until unaccept., toxicity occurs. See lit.
Acute myeloid leukaemia (AML): Indic. in comb. with standard induct. and consolidat. chemother. followed by single-agent maintenan. ther. for adult. with newly diagnos. acute myeloid leukaemia (AML) who have an FLT3 mutat.
Advanc. system. mastocytosis (advanced SM): Tmt. of adult pts. with advanc. system. mastocytosis (advanced SM).
C/I: Hypersens. Concom. admin. of potent CYP3A4 induc., e.g. rifampicin, St. John’s Wort (Hypericum perforatum), carbamazepine, enzalutamide, phenytoin.
